Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
20 August 2018 Photo Barend Nagel
WomenOfKovsies Dr Hoppener research affects access of rural youth to university
Dr Mikateko Höppener is also the author of a book titled, Engineering Education for Sustainable Development: A Capabilities Approach, which is based on her PhD research.

Since September 2016, Dr Mikateko Höppener and a team of researchers have been engaged in a four-year long investigation of the multidimensional factors and dynamics that influence low-income learners’ opportunities to access, participate, and succeed in higher education.

Dr Höppener is a Senior Researcher at the university, working under the leadership of Prof Melanie Walker, South African Research Chairs Initiative (SARChI) Chair and Director of the Higher Education and Human Development Research Programme.

Women in academia

Dr Höppener is part of a team comprised of women whom she constantly learns from and who inspire appreciation.. “I am filled with gratitude for being in the position I am in as a young woman. I have the privilege of working with a team of very inspirational, motivating and encouraging women. The Miratho Project is led by a woman and the rest of the team members are also women,” she says.

Access to higher education
The Miratho Project is undertaken in collaboration with Thusanani Foundation, a youth-led, nonprofit organisation. It is funded by the Economic and Social Research Council, and the UK’s Department for International Development. Rural and township learners from low-income backgrounds are the subject of this multimethod, longitudinal study which tracks their progress into higher education and through to employment.

Among its key objectives, Miratho aims to develop a multidimensional learning outcomes index as an instrument of public debate and guiding government policy. As such it contributes to transforming and decolonising higher education.  

News Archive

Nano research at the UFS opens door to smart drugs
2011-06-27

 

Prof. Lodewyk Kock, outstanding professor in our Department of Microbial, Biochemical and Food Biotechnology

Novel antifungal, anticancer and anti-malaria drugs that have been identified in the research of Prof. Lodewyk Kock, outstanding professor in the Department of Microbial, Biochemical and Food Biotechnology at our university, will be disclosed later this year at major international conferences in Asia, Europe and the USA. Prof. Kock will be the keynote speaker at these conferences. 

His presentations will be based on the department’s discovery of yeast assays linked to a new nanotechnology for medicine. The assays were recently discovered by his group and can be applied in the development of novel antifungal, anticancer and anti-malaria drugs.
 
Prof. Kock’s focused research at the university, which now also includes his novel nanotechnology for Biology, began in 1982 in collaboration with Prof. Pieter van Wyk (Centre for Microscopy). He recently collaborated with Prof. Hendrik Swart (Department of Physics).
 
Prof. Kock says the development of novel anti-malaria drugs in particular is getting attention across the world due to the high rates of morbidity and mortality caused by the disease worldwide. Approximately 225 million people are infected annually and about a million (many in Africa) die each year. “Many potential smart drugs have been identified with this research and should now be tested further,” says Kock.
  
These new drugs will be disclosed during Prof. Kock’s keynote addresses at the International Conference and Exhibition on Pharmaceutical Regulatory Affairs in Baltimore, USA, from 6 to 7 September 2011, the Medichem 2011 in Beijing, China from 9 to 11 August 2011 and the XVI Congress of European Mycologists in Greece, from 19 to 23 September 2011.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept